Progressive Myoclonus Epilepsy and Beyond: A Systematic Review of SEMA6B-related Disorders

Abstract

Progressive myoclonus epilepsy (PME) is a rare, clinically and genetically heterogeneous epilepsy syndrome, and pathogenic variants in the semaphorin 6B (SEMA6B) gene have recently been reported to be among the causes of PME. Cases with pathogenic variants in the SEMA6B gene are extremely rare, only a limited number of cases have been reported in the literature. In this systematic review, we aimed to present a summary of a PME case in which a heterozygous nonsense variant of c.2086C > T p.(Gln696*) in the SEMA6B gene was detected in the etiology and other cases with SEMA6B pathogenic variant in the literature. Except for our case, 35 cases from 12 studies were included. The main clinical findings in these patients were cognitive problems, seizures, gait and speech disturbances, and cognitive and/or motor regression, and they had a wide spectrum of severity. Response to antiseizure medications was also highly variable, almost half of the patients had pharmacoresistant seizures. Patients were divided into four different phenotypic groups according to their clinical presentations: PME (18/36), developmental and epileptic encephalopathy (13/36), neurodevelopmental disorder (4/36), and epilepsy (1/36), respectively. In conclusion, although SEMA6B has been associated with PME, it may actually cause a much broader phenotypic spectrum. Due to their extreme rarity, our knowledge of SEMA6B-related disorders is limited. As with all other rare diseases, each new SEMA6B-related disorder case could contribute to a better understanding of the disease. A better understanding of the disease may allow the development of specific treatment options in the future.

Keywords

SEMA6B - neurodegenerative disorders - SEMA6B-related disorders - progressive myoclonus epilepsy - PME-11

Publication History

Received: 17 March 2024

Accepted: 14 October 2024

Accepted Manuscript online:
17 October 2024

Article published online:
04 November 2024

• References

• 1 Marseille Consensus Group. Classification of progressive myoclonus epilepsies and related disorders. Ann Neurol 1990; 28 (01) 113-116
• 2 Cameron JM, Ellis CA, Berkovic SF. ILAE Genetics Commission, ILAE Genetic Literacy Task Force. ILAE Genetics Literacy series: progressive myoclonus epilepsies. Epileptic Disord 2023; 25 (05) 670-680
• 3 Xiaozhen S, Fan Y, Fang Y. et al. Novel truncating and missense variants in SEMA6B in patients with early-onset epilepsy. Front Cell Dev Biol 2021; 9: 633819
• 4 Courage C, Oliver KL, Park EJ. et al. Progressive myoclonus epilepsies-residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes. Am J Hum Genet 2021; 108 (04) 722-738
• 5 Canafoglia L, Franceschetti S, Gambardella A. et al. Progressive myoclonus epilepsies: diagnostic yield with next-generation sequencing in previously unsolved cases. Neurol Genet 2021; 7 (06) e641
• 6 Krämer G. Progressive myoclonic epilepsies—English version. Z Epileptol 2022; 35 (Suppl. 02) 127-131
• 7 Hamanaka K, Imagawa E, Koshimizu E. et al. De novo truncating variants in the last exon of SEMA6B cause progressive myoclonic epilepsy. Am J Hum Genet 2020; 106 (04) 549-558
• 8 Castellotti B, Canafoglia L, Freri E. et al. Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes. Epilepsia Open 2023; 8 (02) 645-650
• 9 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372 (71) n71
• 10 Riney K, Bogacz A, Somerville E. et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022; 63 (06) 1443-1474
• 11 Scheffer IE, Berkovic S, Capovilla G. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58 (04) 512-521
• 12 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 13 Chen Y, Yang X, Yan X, Shen L, Guo J, Xu Q. A novel SEMA6B variant causes adult-onset progressive myoclonic epilepsy-11 in a Chinese family: a case report and literature review. Front Genet 2023; 14: 1110310
• 14 Cordovado A, Schaettin M, Jeanne M. et al. SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance. Hum Mol Genet 2022; 31 (19) 3325-3340
• 15 Frankel E, Podder A, Sharifi M. et al. Genetic and protein network underlying the convergence of Rett-Syndrome-like (RTT-L) phenotype in neurodevelopmental disorders. Cells 2023; 12 (10) 1437
• 16 Herzog R, Hellenbroich Y, Brüggemann N. et al. Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy. Ann Clin Transl Neurol 2021; 8 (07) 1524-1527
• 17 Li Q, Liu M, Huang DP. et al. A de novo SEMA6B variant in a Chinese patient with progressive myoclonic epilepsy-11 and review of the literature. J Mol Neurosci 2021; 71 (09) 1944-1950
• 18 Duan J, Chen Y, Hu Z. et al. Non-convulsive status epilepticus in SEMA6B-related progressive myoclonic epilepsy: a case report with literature review. Front Pediatr 2022; 10: 859183
• 19 Shu L, Xu Y, Tian Q. et al. A frameshift variant in the SEMA6B gene causes global developmental delay and febrile seizures. Neurosci Bull 2021; 37 (09) 1357-1360
• 20 Zhao J, Tang J, Huang J. et al. Progressive myoclonic epilepsy caused by SEMA6B gene variations: a case report (Article in Chinese). J Clin Pediatr 2022; 40 (09) 705-709
• 21 Andermatt I, Wilson NH, Bergmann T. et al. Semaphorin 6B acts as a receptor in post-crossing commissural axon guidance. Development 2014; 141 (19) 3709-3720